Why does sex become painful and desire disappear during menopause?
Painful sex in menopause is caused by Genitourinary Syndrome of Menopause (GSM) — estrogen decline thins vaginal tissue, reduces lubrication, and removes elasticity. Loss of libido is driven separately by testosterone decline, which is the primary hormonal driver of female desire. Both are progressive without treatment, both are treatable, and most women are never offered a solution because the conversation never happens. This article covers what's causing it, what the evidence supports, and how to start addressing it.
Let me tell you something I hear from women constantly — and almost never in the first conversation.
Sex started to hurt. Or it stopped feeling like anything at all. Or they simply stopped wanting it, and then they stopped thinking about it, and then they started quietly avoiding any situation where it might come up. Not because they didn't love their partner. Not because anything was wrong with their marriage. But because their body had changed in ways nobody warned them about, and the silence around it felt easier than the explanation.
I'm here to break that silence. Not because it's easy to talk about — but because staying quiet is costing you more than you know.
If you are in perimenopause or menopause and your sex life looks nothing like it did five years ago, you are not broken. You are not "letting yourself go." You are not failing your relationship. You are experiencing a set of biological changes that affect up to three quarters of women at this life stage — and that most doctors never proactively address, and most women never bring up, because nobody taught us that this was a medical issue with real, evidence-based solutions.
This article covers everything: why it's happening, what it's called, what actually helps, and how to have the conversation you've been putting off. We're going to name things plainly — including the things your last gynecology appointment skipped over. Because the truth, even when it's uncomfortable, is always better than another year of silent avoidance.
What's Actually Happening in Your Body
The changes you're experiencing are not random and they are not permanent by default. They follow a specific biological cascade — and understanding it is the first step toward doing something about it.
The Estrogen Decline
Estrogen is not just a "reproductive hormone." It is essential tissue maintenance. When estrogen levels drop — which happens gradually through perimenopause and more sharply at menopause — the effects on vaginal and urinary tissue are direct and progressive.
The vaginal walls thin. They lose collagen and elasticity. Natural lubrication decreases significantly. The vaginal pH becomes more alkaline, making tissue more vulnerable to irritation and infection. The clitoris and labia may become less sensitive. All of this has a name, and knowing it matters.
It's called Genitourinary Syndrome of Menopause, or GSM. This is the clinical term that replaced the older phrase "vaginal atrophy" — because atrophy implies deterioration that can't be reversed, and GSM can be treated. GSM affects the vagina, vulva, and urinary tract together, which is why many women also notice increased urinary urgency, recurrent UTIs, or discomfort that isn't strictly sexual. GSM is estimated to affect 27–84% of postmenopausal women, and unlike hot flashes — which often diminish over time — GSM is progressive. It tends to worsen without intervention (Portman & Gass, Menopause, 2014).
Note: A dedicated deep-dive on GSM is available at [LINK: GSM Pillar Stub — Pending]. This article covers sexual function specifically.
The Testosterone Piece
Women produce testosterone too — and it peaks in our twenties, then declines steadily through midlife. By menopause, many women have testosterone levels significantly lower than they did at 25. Testosterone is the primary driver of libido and sexual arousal in women. When it drops, desire often drops with it — not gradually, not ambiguously, but concretely. You stop thinking about sex. Stimulation that used to feel pleasurable may feel neutral or nothing at all.
This is not a character flaw. It is not a sign that you are no longer "that kind of woman." It is physiology.
The Oxytocin and Dopamine Layer
Estrogen plays a regulatory role in dopamine and serotonin signaling. As estrogen declines, some women experience a blunting of reward response — the brain simply generates less anticipation and pleasure from connection, intimacy, and desire. Oxytocin — sometimes called the bonding hormone — is also affected by hormonal shifts. Women who describe feeling "emotionally flat" or "disconnected" from their partners are often experiencing this neurological layer on top of the physical tissue changes.
This is why the experience often feels so confusing: it is not that you don't love your partner. It is that the biological machinery that translates love into desire has been disrupted at the hormonal level.
The Silence That's Making This Worse
Here is what the data shows, and what I have heard from women directly: the conversation never happens. Not with the doctor. Not with the partner. Not even with close friends who are going through exactly the same thing.
I didn't have it either. For almost two years I avoided intimacy, deflected, made excuses — and said nothing to anyone, including my doctor. I thought I was the only one managing it this quietly. I wasn't. Neither are you.
Women are privately Googling "why does sex hurt after menopause" at midnight. They are avoiding intimacy and hoping their partners don't notice. They are quietly grieving something they can't quite name — and they are doing it alone.
Why It Doesn't Come Up at Appointments
Your doctor's appointment is ten minutes. The checklist covers blood pressure, cholesterol, mammogram referrals. Unless you walk in and say the words — "sex is painful" or "I have no libido" — it will not come up. And most women don't say those words. Because they're embarrassed. Because they've been conditioned to think this is just part of aging. Because somewhere along the way they absorbed the message that desire is something younger women have and midlife women manage.
None of that is true. And the consequence of that silence is that women are living with treatable conditions for years, sometimes decades, without intervention.
What Your Partner Is Probably Thinking
This is the part that breaks relationships. When a woman begins avoiding sex — even unconsciously, even for entirely physiological reasons — her partner often interprets it as personal rejection. "She's not attracted to me anymore." "Something is wrong between us." "She's checked out."
And so the partner pulls back too. Distance accumulates. Resentment quietly grows on both sides — hers, because she feels pressured and misunderstood; his (or hers), because they feel unwanted. A treatable medical condition becomes a relational wound.
"A treatable medical condition is being quietly misread as the end of desire — and it's creating distance that doesn't have to exist."
Seventy percent of women in one survey said that treatment for their symptoms would have positively impacted their relationship and potentially avoided breakdown (Newson Health, 2022). The information existed. The treatments existed. The conversation just never happened.
What Actually Helps: The Full Treatment Landscape
This is the section most women came here for — and I'm going to give it to you straight, without minimizing anything and without overpromising. Every option below has evidence behind it. None of them are miracle cures. Most of them work remarkably well when used correctly and consistently.
Non-Hormonal Topical · First Line for Dryness
Vaginal Moisturizers and Lubricants
These are two different things, and the distinction matters. Lubricants are used during sexual activity to reduce friction and discomfort. Moisturizers are used regularly — several times per week — to restore moisture to vaginal tissue over time, independent of sex. If you are only using a lubricant during intercourse and wondering why it doesn't solve the problem, this is why.
The evidence-backed options are Revaree (a hyaluronic acid vaginal insert, non-hormonal, used twice weekly) and Replens (a long-acting moisturizing gel). Both have clinical support. They work differently, for different women, and the choice between them is worth understanding. Revaree is my recommended starting point for most women because of its hyaluronic acid mechanism and non-hormonal profile — but the full comparison is in the dedicated article below.
Hormonal — Local Only · High Evidence Base
Vaginal Estrogen
This is not the same as systemic hormone therapy. I want to say that clearly, because the word "estrogen" stops many women in their tracks — and the fear is understandable given years of conflicting headlines. But vaginal estrogen is applied locally, has minimal systemic absorption, and has a very different safety profile from oral or patch HRT.
Vaginal estrogen directly addresses the tissue-level changes of GSM. It rebuilds vaginal wall thickness, restores elasticity, improves lubrication, and reduces painful intercourse. Available forms include cream, tablet, suppository, and ring. The evidence is strong (Lethaby et al., Cochrane Review, 2016), and major menopause societies — including NAMS — consider it safe for the majority of women, including many who cannot use systemic estrogen.
If your doctor has not offered you vaginal estrogen, you are allowed to ask for it. Write that down. Take it with you to your next appointment.
Hormonal — Emerging Evidence · Worth Discussing
Testosterone Therapy for Libido
Testosterone therapy for women's libido is currently off-label in the United States — meaning it's not FDA-approved for this specific use, though it is used and prescribed by many menopause specialists. The evidence base is genuine and growing. A 2019 systematic review published in The Lancet Diabetes & Endocrinology found that testosterone therapy improved sexual function, desire, arousal, and satisfaction in postmenopausal women (Davis et al., 2019).
This is not a fringe option. It is a legitimate clinical conversation — one that requires a provider who takes women's sexual health seriously. If your current provider dismisses the question, a menopause specialist (many can be found through the Menopause Society's provider directory) is worth seeking out.
Non-Hormonal Oral · For Women Who Cannot Use Estrogen
Bonafide Ristela
For women who cannot or prefer not to use any form of hormonal therapy, Bonafide's Ristela is a non-hormonal oral supplement for arousal and sexual function, formulated with pycnogenol and L-arginine. The evidence base is more limited than vaginal estrogen or testosterone, but it exists — a randomized controlled trial showed improved sexual function scores versus placebo (Stute et al., 2018). It is not a libido switch. It is a supportive option for women in the non-hormonal lane.
Physical Therapy · Underused and Underrated
Pelvic Floor Rehabilitation
Pelvic floor dysfunction — which often develops or worsens in menopause due to tissue changes and decreased estrogen — is a significant contributor to painful intercourse that neither lubricants nor hormones will fully address on their own. Pelvic floor physical therapy, or targeted exercises, can restore function, reduce pain, and improve sexual sensation.
This is covered in full in the dedicated article below. If painful sex is your primary concern, do not skip this section of your treatment plan.
The Conversation You've Been Avoiding
Understanding your own biology is one thing. Talking to your partner about it is another. For many women, this is the harder part — not because their partner is unsympathetic, but because they don't know where to start, or because they've already let the distance build long enough that it feels like a bigger conversation than it was six months ago.
Here is the thing about that conversation: it doesn't have to be a crisis intervention. It can be information sharing. It can be an invitation. And it goes better when it's framed as something happening to your body — not something that has changed about your feelings.
What to say — and how to frame it
And if you are reading this while your partner sleeps in the next room, and you have been quietly carrying this alone for months — I want you to hear this clearly: the distance you're feeling is not inevitable. It is not a verdict on your relationship. It is a gap created by biology and silence, and both of those things can be addressed.
Is This Permanent? The Libido Question You're Afraid to Ask
The fear underneath all of this — the one that most women don't say out loud — is: What if this is just who I am now? What if desire is something that happened to me when I was younger, and now it's gone?
I want to answer that directly, without false reassurance and without cruelty.
For most women, low libido in menopause is not permanent. It is the result of treatable physiological changes. Women who address the tissue-level changes of GSM, who address testosterone decline if appropriate, and who remove the pain element from sex — many report meaningful improvements in desire, arousal, and satisfaction. The evidence is not ambiguous on this.
What is true is that the earlier you address it, the better. GSM is progressive. Vaginal tissue that has thinned over five years is harder to restore than tissue that has been treated for six months. This is not meant to alarm you — it is meant to give you a reason to act now rather than continue waiting for things to improve on their own.
What is also true is that desire is not a purely physical experience. Stress, sleep disruption, relationship distance, and self-image all play into it. Treating the biology matters enormously — and it's also not the complete picture. Women who report the most progress are the ones who address the physical and the relational simultaneously.
Reclaiming your sexuality in midlife is not vanity. It is not a luxury. It is an act of health — for you, and for the relationship you've built.
"You are not out of options. You are, most likely, undertreated — which is a very different thing."
Questions Women Ask Most
Sex becomes painful during menopause primarily because estrogen decline causes vaginal tissue to thin, lose elasticity, and produce less natural lubrication — a condition called Genitourinary Syndrome of Menopause (GSM). The vaginal walls become more fragile and friction during intercourse causes pain, tearing, or burning. GSM affects an estimated 27–84% of postmenopausal women and is progressive without treatment. Effective options include vaginal moisturizers such as Revaree, vaginal estrogen, and pelvic floor rehabilitation.
Loss of libido in menopause is driven primarily by the decline of testosterone — the main hormonal driver of sexual desire and arousal in women. Testosterone levels peak in a woman's twenties and decline gradually through midlife. Estrogen decline also disrupts dopamine and oxytocin signalling, which further reduces desire and emotional connection. Low libido in menopause is a physiological state, not a personal failing — and for most women it is treatable.
GSM is the clinical term for the collection of symptoms caused by estrogen-related changes to the vagina, vulva, and urinary tract during menopause. Symptoms include vaginal dryness, burning, irritation, painful intercourse, urinary urgency, and recurrent UTIs. Unlike hot flashes, which often improve over time, GSM is progressive — symptoms worsen without treatment. It is estimated to affect 27–84% of postmenopausal women (Portman & Gass, Menopause, 2014).
For most women, yes. Low libido in menopause is not permanent — it is the result of treatable hormonal changes. Women who address the tissue-level changes of GSM, consider testosterone therapy if appropriate, and remove the pain element from sex frequently report meaningful improvements in desire and arousal. The earlier treatment begins the better, as GSM is progressive. A conversation with a menopause-informed provider about testosterone therapy and vaginal estrogen is the recommended starting point.
Yes. Vaginal estrogen is applied locally, has minimal systemic absorption, and directly rebuilds vaginal wall thickness, restores elasticity, and improves lubrication. It is the most effective treatment for GSM-related painful sex. A Cochrane systematic review (Lethaby et al., 2016) confirms strong evidence for its efficacy. NAMS considers vaginal estrogen safe for most women, including many who cannot use systemic hormone therapy. If your doctor has not offered it, you are allowed to ask for it specifically.
Lubricants reduce friction during sex; moisturizers address ongoing tissue health independently of sexual activity. For vaginal moisturizers, Revaree (hyaluronic acid vaginal insert, used twice weekly) has strong clinical evidence including a 2023 RCT showing non-inferiority to vaginal estrogen for dryness and painful sex. Replens (polycarbophil gel) is a well-studied, accessible alternative for mild dryness. Both are non-hormonal and safe for breast cancer survivors. A full comparison is in the dedicated article: Revaree vs Replens.
No. For most women, low libido in menopause is caused by treatable physiological changes — primarily testosterone decline and the pain associated with GSM. Women who receive appropriate treatment, including vaginal estrogen, testosterone therapy where suitable, and vaginal moisturizers, frequently experience meaningful recovery of desire and sexual satisfaction. The key is identifying and treating the underlying cause rather than accepting low libido as a permanent state.
You deserve real answers — not another dismissal.
The StillHer Clarity Kit gives you the evidence-based framework for understanding what's happening in your body and what to do about it. Built specifically for women in perimenopause and menopause.
Get the Clarity Kit → Or start with the non-hormonal option: Revaree — Samantha's recommended first step for dryness and painful sex →
Clinical References
- Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The Menopause Society. Menopause. 2014;21(10):1063–1068.
- Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews. 2016;(8).
- Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. The Lancet Diabetes & Endocrinology. 2019;7(4):277–278.
- Stute P, et al. Pycnogenol and L-arginine in the treatment of female sexual dysfunction. Phytomedicine. 2018.
- Newson Health / Family Law Menopause Project. Survey of 1,000 divorced women on menopause and relationship breakdown. 2022.
- Millheiser LS, et al. Is female sexual dysfunction associated with type and duration of menopause? Journal of Sexual Medicine. 2010;7(4):1637–1644. (Ohio State Wexner Medical Center research; prevalence data cited in institutional menopause health resources.)
- Blumel JE, et al. Impact of menopausal symptoms on personal and work-related activities and on quality of life — a cross-sectional study. Maturitas. 2011;70(1):19–24. n=254 postmenopausal women; 67.7% reported negative sexual life impact.
- Rosenfeld MJ. Who wants the breakup? Gender and breakup in heterosexual couples. Social Forces. 2017.